artnet AG: Artnet Publishes Annual Report Showing Accelerated Growth and Increased Revenue
4.5.2022 18:29:00 EEST | Business Wire | Press release
Artnet AG, the leading platform for art market data and media, and the global marketplace for fine art, today published its Annual Report for the financial year 2021. As reflected in the report, Artnet accelerated its growth, with total revenue increasing 14% to 24,6 Million USD. In line with expectations, the Company recorded net income of -887k USD in 2021 as a result of strategic investments in key hires and product development. During the 2021 financial year, Artnet reached significant milestones, growing its market share and customer base. The company also streamlined its segmentation into three core product areas: Data, Marketplace, and Media. "2021 set the foundation for accelerated growth at Artnet as the art industry continues its shift online. Over the coming years we will focus on unlocking the synergies that exist within our diversified business model in order to provide the platform for its digital future.” commented Artnet CEO Jacob Pabst.
Within the Media segment, Artnet experienced record-breaking growth, with a 40% increase in revenue and a 27% increase in traffic leading to over 100 million pageviews on Artnet News. The introduction of Artnet News Pro in May 2021 provides the media segment with an additional revenue stream through a partial-paywall subscription model targeting Artnet’s most engaged readership. In total Artnet achieved 30% traffic growth across the platform, reaching over 200 Million pageviews and making it the most visited Fine Art platform globally.
Within the Marketplace segment, Artnet Auctions achieved robust results during the financial year 2021, cementing and building upon the 25% record revenue growth of 2020. Artnet Auctions' average transaction value (ATV) increased 13% YoY to $16,100, while fee-based revenue increased 6% year-over-year to 5.1 million USD. Artnet, therefore, is the fourth largest auction house for online fine art sales behind Sotheby's, Christie's and Phillips. The introduction of ArtNFT, a curated web-3 enabled, ethereum-compatible NFT platform generated over 500k USD in sales during the inaugural sale in Q4 of 2021.
The Data segment reached the historic milestone of 15 million auction results. Data inputs increased 23.5% YoY, and Artnet’s Data continues to drive decision making as the critical pricing tool for the industry. In Q2 of 2022, Artnet will relaunch the Price Database following a complete rebuild that will feature a revamped user experience, mobile first design, and a new API enabled data architecture.
“Artnet’s Data, Media, and Marketplace segments are unique in the market, with each representing a critical tool for the global art industry,” said Artnet CSO Albert Neuendorf. "These three pillars provide the foundation for a fully integrated data-driven online transactional ecosystem, and the renewed Price Database is a key step to realizing that future.” Along with the complete rebuild of the Price Database there are important additional improvements which will already have an effect on revenues in 2022. A unified navigation, a full revamp of Artnet News, and important key page redesigns will significantly increase traffic and engagement.
In 2020, Artnet adopted an ESG (Environmental, Social, Corporate Governance) strategy, defined key areas of responsibility, and set specific goals to be implemented by 2025. The Annual Report 2021 includes Artnet’s audited 2021 ESG report. By reporting on ESG initiatives, Artnet pursues its principle of spearheading positive change and sustainable business practices in the art market. The annual report for the financial year 2021 is available at artnet.com/investor-relations/annual-reports/
Further Investor-relations related news and publications can be found here: http://www.artnet.com/investor-relations/
About ArtneArtnet has an unparalleled 55 million users annually, making it the largest global platform for fine art. Founded in 1989, Artnet has revolutionized the way people discover, research, and collect art today. Artnet’s Data provides mission-critical resources for the art industry, encompassing more than 15 million auction results and AI- and ML-driven analytics, further driving transparency and insight into the art market. Artnet’s marketplace connects leading galleries and auction houses with its global audience, offering a curated selection of over 250,000 artworks for sale worldwide. Artnet Auctions, the pioneering online-only auction platform, offers unprecedented reach, liquidity, and efficiency for buyers and sellers. Artnet News covers the events, trends, and people shaping the global art market with up-to-the-minute analysis and expert commentary. It is the single most-read news publication in the fine art industry, with a rapidly growing, dedicated audience. Together, Artnet’s broad synergistic product offering provides a comprehensive ecosystem that drives and informs the modern art market.
Artnet AG is listed in the Prime Standard of the Frankfurt Stock Exchange, the segment with the highest transparency standards. The majority of operations are headquartered in New York at its wholly-owned subsidiary, Artnet Worldwide Corporation, a New York based entity founded in 1989. Artnet Worldwide Corp. owns a London based subsidiary, Artnet UK Ltd.
ISIN: DE000A1K0375
LEI: 391200SHGPEDTRIC0X31
Additional features: File: https://eqs-cockpit.com/c/fncls.ssp?u=74f4925c4cd5f6ba2fadca3260a8298b
File description: Artnet Annual Report 2021
| Language: | English |
| Company: | artnet |
| AG Oranienstraße 164 | |
|
10969 |
|
| Berlin | |
| Germany | |
| Phone: | +49 (0)30 20 91 78 -0 |
| Fax: | +49 (0)30 20 91 78 -29 |
| E-mail: | info@artnet.de |
| Internet: | www.artnet.de |
| ISIN: | DE000A1K0375 |
| WKN: | A1K037 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, |
| Dusseldorf, Stuttgart, Tradegate Exchange |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220504005849/en/
Contact information
Sophie Neuendorf
sneuendorf@artnet.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 02:35:00 EEST | Press release
Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Capability of Next Generation Earth Observation Satellites Project Title: Source-Specific CO2 Emission and Uptake Monitoring through Satellite Constellation and Ai
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom